$4.990
+0.308 (+6.17%)收盤時
NUS 資訊
NUS 事件
Cuts FY26 Revenue View to $1.28B-$1.35B
Cuts FY26 revenue view to $1.28B-$1.35B from $1.35B-$1.5B.
Sees Q3 Revenue of $310M to $340M
Sees Q3 revenue $310M-$340M.
Sees Q2 Revenue of $330M-$360M
Sees Q2 revenue $330M-$360M, one estimate $361M.
Company Confirms FY26 Revenue Outlook of $1.35B to $1.5B
Backs FY26 revenue view $1.35B-$1.5B, one estimate $1.43B.
Nu Skin Q1 Revenue at $320.6M, Below Estimate
Reports Q1 revenue $320.6M, one estimate $329.7M. "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environment," said Ryan Napierski, Nu Skin president and CEO. "As we move through 2026, we are focused on empowering our sales leaders to scale our intelligent wellness platform with our latest innovation, Prysm iO(TM), ahead of our full consumer rollout in the second half. We also continue to invest in laying the groundwork to expand our presence in emerging markets, including the formal launch of India anticipated in late 2026, while continuing to improve our operational discipline to return value to shareholders."
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。